Navigation Links
ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met,Inhibitor, for Oral Presentation at ASCO

in experimental metastatic models of colon cancer

About ArQule

ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are designed to affect key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy(R) (ACT). The Cancer Survival Protein modulation platform has generated a clinical-stage product designed to inhibit a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company's lead ACT program, based on the E2F-1 pathway, is partnered with Roche. For more information, please visit www.arqule.com.

This press release contains forward-looking statements regarding the Company's Phase 1 trial with ARQ 197 and Phase 2 trials with ARQ 501. These statements are based on the Company's current beliefs and expectations, and are subject to risks and uncertainties that could cause actual results to differ materially. Positive information about early stage clinical trial results does not ensure that later stage or larger scale clinical trials will be successful. For example, ARQ 197 and ARQ 501 may not demonstrate promising therapeutic effect; in addition, they may not demonstrate an appropriate safety profile in current or later stage or larger scale clinical trials as a result of known or as yet unanticipated side effects. The results achieved in ongoing or later stage trials may not be sufficient to meet applicable regulatory standards. Problems or delays may arise during clinical trials or in the course of developing, testing
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:9/2/2015)... 2015 Demers Ambulances is proud to announce it ... dealer for the states of Mississippi , ... . "This will enable Demers to effectively ... , Executive Vice-President for Demers Ambulances. "Emergency Equipment Professionals has ... and Alabama , giving them a strategic ...
(Date:9/2/2015)... Sept. 2, 2015  MiMedx Group, Inc. (NASDAQ: ... human amniotic tissue and patent-protected processes to develop ... Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic ... inaccurate statements published by the Musculoskeletal Transplant Foundation ... 2015. MTF,s September 1st press release ...
(Date:9/2/2015)... 2, 2015 Unilife Corporation ("Unilife" or the ... developer, manufacturer and supplier of injectable drug delivery systems, ... of interest, the Company,s Board of Directors has engaged ... of strategic alternatives to maximize shareholder value. ... during the review process may include a possible sale ...
Breaking Medicine Technology:Demers Ambulances has named Emergency Equipment Professionals (EEP) Inc. as their dealer for the states of MS, AL and TN 2MiMedx Corrects A Second Inaccurate MTF Press Release 2MiMedx Corrects A Second Inaccurate MTF Press Release 3Unilife Announces Review of Strategic Alternatives 2
(Date:9/3/2015)... ... 03, 2015 , ... DiabetesSisters Welcomes Carol Wysham to Board ... of Carol Wysham, MD, to their esteemed Board of Directors. Dr. Wysham was ... Warren, Matt Stella, Tricia Cedotal, Andrea Thomas, Wanda Nicholson and Vicki Norris. As ...
(Date:9/3/2015)... ... ... A scar is an unavoidable result of incision or injury to the skin. Unsightly as ... itself. The appearance of a scar is dependent on many factors – the size and ... scars fade to near invisibility on their own over a period of months,” says ...
(Date:9/3/2015)... ... 03, 2015 , ... The new In-Office whitening kit from ... The Clinicians Report is a leading information source to the dental industry. Product ... Whiter Image's In-Office whitening kits were favorably validated for use in the dental ...
(Date:9/3/2015)... ... September 03, 2015 , ... James Earl Jones will be ... In this episode, James Earl Jones will introduce a segment that discusses why it ... and how workplace wellness can be fostered in any working environment. , Employers are ...
(Date:9/2/2015)... ... September 03, 2015 , ... The Aspen Clinic (TAC), located in ... towards kick-starting and inspiring wellness in the Roaring Fork Valley and beyond. , Amanda ... whole mind-body approach to fitness - we are much more than a gym. ...
Breaking Medicine News(10 mins):Health News:Carol H. Wysham, MD, Joins DiabetesSisters Board of Directors 2Health News:Do I Have To Live With That Scar? 2Health News:Do I Have To Live With That Scar? 3Health News:Do I Have To Live With That Scar? 4Health News:Whiter Image Products Get Positive Rating From The Clinicians Report 2Health News:James Earl Jones Hosts a New "Voices In America" Piece on Making the Workplace Healthier 2Health News:TAC Introduces New Retreats for Fall Fitness 2
... , ... announces that their Electronic Health Record, Perfect Care EHR® ... Information Technology (CCHIT®) and is Preliminary ARRA 2011 certified, ... Use Objectives for Eligible Providers under the American Recovery ...
... drug cocktail might be the right mix to fight ... Details of a new study supporting this approach suggest ... work again. The findings were presented today at the ... involves post-menopausal women whose advanced breast cancers are fueled ...
... that could prevent another blood clot, study finds , ... stroke survivors don,t take medications that can reduce their risk ... stroke is caused by blocked blood flow in the brain. ... ischemic stroke. These include blood thinners (antithrombotic medications), of which ...
... , , , WINSTON-SALEM, N.C., Dec. 11 ... officers once again put the spotlight on mass murder in ... killings at Fort Hood, the Washington case raised questions about ... rampage. , Andrew Smiler, an assistant professor of psychology at ...
... , DALLAS, Dec. 11 For their ... rehabilitation for younger, more active cardiac patients, the Cardiac ... Heart and Vascular Hospital was recently awarded the Innovation ... Rehabilitation (AACVPR). The award acknowledges programs that have enhanced ...
... survey respondents were under 35 when they sought treatment , ... that age is an important factor in the success of ... 18 and older, including 125 women who,ve had fertility treatment. ... were under age 35 when they first sought medical advice ...
Cached Medicine News:Health News:NCG Medical, Perfect Care EHR Achieves Preliminary ARRA 2011 Certification From CCHIT 2Health News:NCG Medical, Perfect Care EHR Achieves Preliminary ARRA 2011 Certification From CCHIT 3Health News:Clinical trial advances new approach to re-sensitizing breast cancer 2Health News:Mass Murderers: Why Do They Kill? 2Health News:Baylor Hamilton Heart Hospital Honored for Innovative Rehabilitation Program 2Health News:Baylor Hamilton Heart Hospital Honored for Innovative Rehabilitation Program 3Health News:Women Aren't Waiting to Seek Infertility Help 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: